Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon

NCT00378521 is registered in ClinicalTrials.gov with MediQuest Therapeutics as lead sponsor.

NCT NCT00378521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00378521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon
Lead sponsor
MediQuest Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2006
Completion date
July 31, 2006
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

raynaud's disease, raynaud's disease secondary to autoimmune disease, raynaud's disease secondary to scleroderma